Clinical features and prognosis of COVID-19 patients with metabolic syndrome: A multicenter, retrospective study

• Jian Wang ^[3] ; Li Zhu ^[1] ; Longgen Liu ^[4] ; Xuebing Yan ^[5] ; Leyang Xue ^[6] ; Songping Huang ^[7] ; Biao Zhang ^[8] ; Tianmin Xu ^[4] ; Fang Ji ^[5] ; Chunyang Li ^[5] ; Fang Ming ^[7] ; Yun Zhao ^[9] ; Juan Cheng ^[10] ; Kang Chen ^[11] ; Xiang-an Zhao ^[12] ; Dawen Sang ^[10] ; Xinying Guan ^[13] ; Xiaobing Chen ^[14] ; Xiaomin Yan ^[3] ; Zhaoping Zhang ^[3] ; Jiacheng Liu ^[2] ; Rui Huang ^[3] ; Chuanwu Zhu ^[1] ; Chao Wu ^[3]
  1. [1] Soochow University

     Soochow University

     China

     
  2. [2] Nanjing University of Chinese Medicine

     Nanjing University of Chinese Medicine

     China

     
  3. [3] Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China
  4. [4] Department of Infectious Diseases, The Third People's Hospital of Changzhou, Changzhou, China
  5. [5] Department of Infectious Diseases, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
  6. [6] Department of Critical Medicine, Huai’an No. 4 People's Hospital, Huai’an, China
  7. [7] Department of Infectious Diseases, Nantong Third People's Hospital, Nantong University, Nantong, China
  8. [8] Department of Quality Control Office, Huai’an No. 4 People's Hospital, Huai’an, China
  9. [9] Department of Infectious Diseases, The Third People's Hospital of Yangzhou, Yangzhou, China
  10. [10] Department of Infectious Diseases, Yancheng Second People's Hospital, Yancheng, China
  11. [11] Department of Tuberculosis, The Third People's Hospital of Changzhou, Changzhou, China
  12. [12] Department of Gastroenterology, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou, China
  13. [13] Department of Neurology, The Affiliated Hospital of Kangda College of Nanjing Medical University, The First People's Hospital of Lianyungang, Lianyungang, China
  14. [14] Department of Emergency, The Affiliated Hospital of Kangda College of Nanjing Medical University, The First People's Hospital of Lianyungang, Lianyungang, China

  Mostrar afiliaciones +
• Localización: Medicina clínica, ISSN 0025-7753, Vol. 158, Nº. 10, 2022, págs. 458-465
• Idioma: inglés
• DOI: 10.1016/j.medcli.2021.05.014
• Títulos paralelos:
  • Características clínicas y pronóstico de los pacientes con COVID-19 y síndrome metabólico: un estudio multicéntrico y retrospectivo
• Texto completo no disponible (Saber más ...)
• Resumen
  • español

    Antecedentes Pocos estudios han investigado el impacto del síndrome metabólico (SM) en la enfermedad por coronavirus 2019 (COVID-19). Describimos las características clínicas y el pronóstico de los pacientes con COVID-19 confirmados con SM durante la hospitalización y después del alta.

    Métodos Se incluyó de forma retrospectiva a 233 pacientes con COVID-19 de los hospitales de 8 ciudades de Jiangsu (China). Se describieron sus características clínicas y se analizaron los factores de riesgo de enfermedad grave mediante un análisis de regresión logística.

    Resultados De los 233 pacientes, 45 (19,3%) tenían EM. La mediana de edad de estos pacientes con EM fue significativamente mayor que la de los pacientes sin él (53,0 años frente a 46,0 años; p = 0,004). No hubo diferencias significativas en cuanto a los síntomas clínicos, las imágenes de TC torácica anormales y los fármacos de tratamiento entre los 2 grupos. Hubo más pacientes con EM que tuvieron enfermedades graves (33,3% frente a 6,4%; p < 0,001) y críticas (4,4% frente a 0,5%; p = 0,037) que los pacientes sin EM. Las proporciones de insuficiencia respiratoria y síndrome de dificultad respiratoria aguda en los pacientes con EM también fueron mayores que en los pacientes sin EM durante la hospitalización. El análisis multivariante mostró que la EM concurrente (odds ratio [OR] 7,668; intervalo de confianza [IC] del 95%: 3,062-19,201; p < 0,001) y la linfopenia (OR 3,315; IC del 95%: 1,306-8,411; p = 0,012) eran factores de riesgo independientes de COVID-19 grave. En una mediana de seguimiento de 28 días tras el alta, se encontró neumonía bilateral en el 95,2% de los pacientes con EM, mientras que solo la presentaron el 54,7% de los pacientes sin EM.

    Conclusiones El 19,3% de los pacientes con COVID-19 tenían EM en nuestro estudio. Los pacientes con COVID-19 y EM son más propensos a desarrollar complicaciones graves y tienen peor pronóstico. Se debe prestar más atención a los pacientes con COVID-19 y EM.

  • English

    Background Few studies have investigated the impacts of metabolic syndrome (MS) on coronavirus disease 2019 (COVID-19). We described the clinical features and prognosis of confirmed COVID-19 patients with MS during hospitalization and after discharge.

    Methods Two hundred and thirty-three COVID-19 patients from the hospitals in 8 cities of Jiangsu, China were retrospectively included. Clinical characteristics of COVID-19 patients were described and risk factors of severe illness were analyzed by logistic regression analysis.

    Results Forty-five (19.3%) of 233 COVID-19 patients had MS. The median age of COVID-19 patients with MS was significantly higher than non-MS patients (53.0 years vs. 46.0 years, P=0.004). There were no significant differences of clinical symptoms, abnormal chest CT images, and treatment drugs between two groups. More patients with MS had severe illness (33.3% vs. 6.4%, P<0.001) and critical illness (4.4% vs. 0.5%, P=0.037) than non-MS patients. The proportions of respiratory failure and acute respiratory distress syndrome in MS patients were also higher than non-MS patients during hospitalization. Multivariate analysis showed that concurrent MS (odds ratio [OR] 7.668, 95% confidence interval [CI] 3.062–19.201, P<0.001) and lymphopenia (OR 3.315, 95% CI 1.306–8.411, P=0.012) were independent risk factors of severe illness of COVID-19. At a median follow-up of 28 days after discharge, bilateral pneumonia was found in 95.2% of MS patients, while only 54.7% of non-MS patients presented bilateral pneumonia.

    Conclusions 19.3% of COVID-19 patients had MS in our study. COVID-19 patients with MS are more likely to develop severe complications and have worse prognosis. More attention should be paid to COVID-19 patients with MS.